|Breathe Easy and Buy Smart|
Breathe Easy and Buy Smart
What a difference a week makes. A week ago, traders and investors sharply sold off equities due to concerns over the possibility of a severe depression in Europe and the potential need for more bailouts. Yields collapsed in the U.S. as the European worry translated into fears of a recession in the U.S. as well. When we had more of the same early last week, along with some poor U.S. bellwether earnings reports, even I was getting depressed.
Then along came “Draghi”. As in Mario Draghi, the head of the European Central Bank who basically drew a line in the sand, took control and said unequivocally that everything will be done to save the euro, which would stave off a possible depression across the pond. It is reminiscent of the early Alan Greenspan years when the former Chairman of the Federal Reserve found ways to give investors the confidence that the world was not coming to an end, despite gloomy outlooks. If he is able to pull it off, Draghi will become a legend for keeping the global economy from collapsing and stock markets from dropping.
This is actually very important because the stock market has been particularly maddening the past several months. Stocks are valued based upon the valuation of financial metrics related to an individual security or industry. Global geo-political or economic factors play a role, as do monetary policies. But stocks were not intended to trade based upon these factors as a primary indicator. Unfortunately, even heading back into last year, performance has been dominated by Europe, global economics and monetary policy, rather than valuation and earnings growth. For the time being, if U.S. investors reduce the importance of the European threat, and focus on domestic issues, we will have a more normalized market, such as what we have experienced the past 2 trading days.
For example, annualized GDP growth slowed to 1.5% during the second quarter of 2012, down from 2.0% in the first quarter of the year. Frankly, consumer spending was unusually high in Q1 and it dropped in Q2, which is why GDP growth slowed. The 1.5% isn’t very good at all, but it is a hell of a lot better than most developed nations right now. Thus, growth should be cheered, as should valuation.
Let’s face it. Consumer stocks are taking it in the chin right now, as many of the results of companies in the sector have been sub-par. The same goes for some segments of technology, notably the semiconductor space. Even some health care stocks are questionable due to the Supreme Court decision on Obamacare. Still, despite these potholes, the valuation of stocks as a whole is favorable.
Investors in the penny stock world can attest to the fact that it has not exactly been the greatest place to be in lately. Volume has been weak, conviction worse, and patience by investors has been slim to none. This is emblematic of the risk concerns at the top of the food chain, i.e. blue chip stocks. If we can feel warm and fuzzy about Europe and get back to brass tacks, risk will not be as great an issue any longer and more money will pour back into equities, including small stocks.
Speaking of small stocks, they really lagged behind their bigger brethren last week. For the week, the DJIA rose 2.0% while the Russell 2000 Index increased by only .5%. Not cool. We are going to work extra hard to find some movers and shakers next week in our daily blogs. In the interim, after the money chases the big stocks, they will come back to us little guys. It may not be until November until they come out in full force, but when they do, we are gonna party like its 2012, because the valuations will be so much more favorable than larger cap stocks.
Patience and prudence will be rewarded so breathe and enjoy the current run, but don’t hold onto stocks for too long and buy stocks on an upswing. And please, please...if a “listed” stock did not go up the past 2 days, it is probably a sign that it won’t in the near future, so stay away. Buying it would be a cardinal sin, don’t you think?
We Forgot One
Last week, when we were putting together our list of small cap dividend plays, we forgot to mention one of our favorites. Don’t worry. It is not too late to buy the stock.
PDL BioPharma, Inc. (NASDAQ—PDLI—$6.81) is yielding 8.8%—and ladies and gentlemen, it is not in danger of suspending it or reducing it for a few quarters at least. PDL BioPharma pioneered the humanization of monoclonal antibodies and, by so doing, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDLI owns a ton of patents in this space and licenses the tech to some of the leading pharma and biopharma firms in the world. As a result, PDLI will generate roughly $375M in revenue this year with EPS of $1.43. The margins are sick since there are basically no expenses—-hence the reason for the dividend. Revenue and EPS should be 20% higher next year, so investors could record strong capital gains and dividends. If it just trades 5x its $1.73 FY13EPS, that is a $10+ stock. What a great model.
Until next week…
Analyst: Robert Goldman
It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This report or newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report or newsletter does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with the FINRA or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com.